The level of BPA exposure of patients is similar to that of consumers. Patient exposure is generally below the current European standard for safe exposure, and thus adverse effects are consequently not expected. However, for specific groups, the level of exposure can be higher than the current European standard.

 

In particular, the exposure of premature infants and young children undergoing long-term medical treatment deserves attention. This group is at risk because of the relatively high level and long period of exposure. Also, given recent indications of possible adverse effects on the immune system of the unborn child and infants, protection of this group deserves special attention. Exposure to BPA can come from tools that are necessary for medical reasons, for example, for the treatment of a child in an intensive care unit.